FOR IMMEDIATE RELEASE
February 11, 2002
Burlington, Ontario

FOR IMMEDIATE RELEASE
March 5, 2002

Burlington, Ontario

THE JENEX CORPORATION ("Jenex" or the "Corporation") (CDNX - JEN), is pleased to announce the addition of Mr. Jacques Tricoire to its Corporate Advisory Committee. Mr. Tricoire brings over thirty years of business development experience in various Health related industries. He becomes the 7th member of the Corporation's Accomplished Advisory Committee (see www.jenexcorp.com). The Advisory Committee is an integral part of the Corporation's strategy to seek experienced professional advisors to assist the Company in achieving its corporate goals.
In 1991 Jacques Tricoire founded and is currently President of SWARM S.A., specializing in niche products for animal health (bee health medicines) and active throughout Europe and North Africa.
Mr. Tricoire and SWARM S.A. have been working with the Thermo Therapy Technology since 1997.

After receiving his Masters Degree in Business Administration in Paris (Ecole des Hautes Etudes Commerciales), he served in various positions in Marketing and Management in Sandoz Pharmaceutical Group (presently Novartis), in France, Brazil and Switzerland. From 1986 to 1991, he was General Manager Europe of' Zoecon, an American Corporation based in Dallas, affiliated to the Sandoz Group, specializing in Public Hygiene and animal health

About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and the E.E.C protect the technology. Approval from regulatory, Therapeutic Products Programme (TPP), in Canada has been received to market their thermal therapy device, over-the-counter (OTC) with the claim "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks". A medical device number has been issued by TPP, in accordance with Medical Device Regulations. Jenex is the first company to receive regulatory approval from a significant regulatory body to make the prevention claim for cold sores.

The Corporation is currently seeking approval from FDA to make a similar marketing claim in the United States. Management of the Corporation expects a response from the FDA in the 2nd quarter of 2002. Regulatory approvals are being pursued in all European countries and Australia.

Jenex is now seeking a strategic corporate partner to license and commercialize their thermal therapy technology. Several Multi-National Companies have signed Confidentiality Agreements and are in various stages of due diligence.

The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market.

“Prevention is the Solution”

For further information, see www.jenexcorp.com or contact:

Michael A. Jenkins, President
The Jenex Corporation
207 - 940 Sheldon Court
Burlington, Ontario L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: Jenex@sprint.ca

The Canadian Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.